Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in metastatic breast cancer (PAINTER01)
NCT02864030Phase 4Completed
- Sponsor
- Ospedale Fatebenefratelli (Medical Oncology)
- Start
- May 2014
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of eribulin in breast cancer, sponsored by Ospedale Fatebenefratelli (Medical Oncology). Started May 2014; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02864030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864030.